The clinical-trial video library, curated.
2,409 videos on trial science, patient experience, operations, technology, and policy — organized into clean sections and topics, updated as new ones are found.
Pat Koochaki on a ZTTK Disease Concept Model
Dr. Pat Koochaki, Senior Principal at ICON, presents a preliminary ZTTK disease concept model built from focus groups with 39 caregivers, to guide outcome measures for future trials, and FDA engagement, for the ZTTK SON-Shine Foundation.
All videos
2,409 videos
15:16 The Imaging Gap in GLP-1 Trials
Prof. Mikael Boesen of Copenhagen University Hospital discusses why GLP-1 knee osteoarthritis trials still enrol patients on 1957 x-ray grading, and when sponsors should use DXA or MRI to measure joint and muscle changes, on The Clinical Trial Vanguard.
56:03 Remote Trials and Digital Endpoints in Underserved Indications
Meri Beckwith of Lindus, Simon Bock of Tiefenbacher Group and ReMEdi trial investigator Beata Godlewska discuss how the fully remote Phase IIa ME/CFS trial captured 22 endpoints per patient and what remote designs offer underserved indications.
45:57 On Research Podcast - Hope, Uncertainty, and the Future of Science
Dr. Josh Fessel shares insights from his experience at the NIH on shifting federal priorities, growing instability, and the risks of inaction for science.
1:10:42 HDBuzz Huntington's Disease Clinical Trial Update
At a Huntington Society of Canada keynote recorded in November 2025, Dr. Tam Maiuri and Dr. Rachel Harding of HDBuzz give an accessible update on Huntington's disease research, clinical trial progress and new treatment approaches.
1:29 LTI-03 and the Phase 2 RENEW Trial in IPF
Brian Windsor, Ph.D., President and CEO of Rein Therapeutics, explains why approved IPF drugs only slow the disease and describes LTI-03, an inhaled peptide that in September 2026 was being evaluated in the Phase 2 RENEW trial.
5:26 Synthetic CDISC Trial Data for EDC Validation
Zifo describes generating synthetic, CDISC-compliant trial subjects from USDM and EDC design exports to test SDTM and ADaM programming across screen failures, dose changes and deviations.
29:05 STIMIT's Non-Invasive Diaphragm Stimulation in the ICU
STIMIT CEO and founder Ronja Müller-Bruhn tells IEEE Pulse how magnetic stimulation of the phrenic nerve aims to preserve diaphragm function in ventilated ICU patients, and discusses its FDA pivotal trials and Health Canada clearance.
6:01 FDA Feedback on Medicus Pharma's Teverelix Phase 2 Trial
Medicus Pharma CEO Dr. Raza Bokhari tells Proactive about FDA feedback and central IRB approval for its Phase 2 ANT-2111-02 trial of Teverelix after acute urinary retention, including injection-site blinding and safety monitoring changes.
2:02 DeLLphi-312: Tarlatamab with Chemoimmunotherapy for First-Line Treatment of ES-SCLC
Second-line tarlatamab improved overall and progression-free survival in a Phase Ib trial in extensive-stage small-cell lung cancer, leading to the Phase III DeLLphi-312 study in the first line.
1:00:25 Optimizing Obesity Endpoints: Early Innovation to Late Differentiation
Clario's eCOA, cardiac safety and medical imaging experts discuss choosing endpoints for obesity drug trials, from early signals that inform dose selection to evidence packages for regulators.
5:11 Neuralink Clinical Trials for Brain Computer Interface and the Dura
Neuralink on inserting its implant's electrode threads through the intact dura into the cortex for the first time in its clinical trials, at Toronto Western Hospital.
18:43 Israel as a Destination for Clinical Research
In a podcast with GlobalData, Oximio's chief commercial officer Zayheda Khan and Israeli QP pharmacist Stanislav Liakhovski discuss Israel as a clinical research destination, its regulatory pathways and start-up times, and clinical trial supply there.
39:24 Why Good Medical Devices Fail: Reimbursement Strategy with Ali Samiian
Greenlight Guru talks to Ali Samiian of Popular Access Advisors about MedTech reimbursement, the FDA's TAP program and the CMS RAPID program.
3:24 SUCCESSOR-2: Mezigdomide in Relapsed Myeloma
At EHA 2026, Meletios Dimopoulos of the National and Kapodistrian University of Athens, Rahul Banerjee of Fred Hutchinson and Katja Weisel of UKE discuss the phase 3 SUCCESSOR-2 trial of mezigdomide with carfilzomib and dexamethasone in relapsed myeloma.
58:24 Analytical Mass Spectrometry Workflow for VAMS and Its Applications in Cardiology and Beyond
Jenny Van Eyk, Professor of Cardiology at Cedars-Sinai, on a mass spectrometry proteomic workflow for volumetric absorptive microsampling, moderated by Neil Spooner of the Patient Centric Sampling Interest Group.
53:52 The TIME Trial: Does Immunotherapy Timing Matter in Melanoma?
Dr. Omid Hamid of The Angeles Clinic, Dr. Ryan Sullivan of Massachusetts General Hospital and colleagues explain the TIME Trial, testing whether earlier-in-the-day immunotherapy affects outcomes in advanced melanoma, for the Melanoma Research Alliance.
1:05:36 Human Challenge Studies in Vaccine Development
In a KEMRI-Wellcome Trust vaccinology webinar, Malik Gibani, clinical associate professor at Imperial College London, explains how human challenge studies contribute to developing safe and effective vaccines.
1:15:46 eTMF Inspection Readiness for Sponsors and CROs
Anna Petrovskaya, QA director at Flex Databases, and Christoph Ortland, CEO of Forschungsdock CRO GmbH, discuss how sponsors and CROs prepare an eTMF for inspection, including content, system validation and access, and handling findings.
1:27:47 Meet the Expert: Shyam Patel, Kevin Strauss, Manar Zaghlula
Shyam Patel, Kevin Strauss and Manar Zaghlula discuss economic and reimbursement perspectives on gene editing therapies.
19:20 From Data Collection to Experience Orchestration: Breaking Trial Silos
In a segment from Medidata's From Dreamers to Disruptors podcast shared by SCDM, panellists from CRO and site backgrounds describe how siloed data management, medical review and central monitoring create rework for sites.
13:27 Prader-Willi Syndrome: Diazoxide Choline Extended Release Improves Hyperphagia
Evelien Gevers, PhD, MD, of Barts Health NHS Trust on the effect of diazoxide choline extended release on hyperphagia in patients with Prader-Willi syndrome.
52:08 Andreas Beust on Running Global Trials as a Small CRO
On Pharma Prescribed, Andreas Beust, CEO of the Bremen CRO GCP Service International and president of ACROS, explains how an alliance of similar-sized CROs lets a small firm run trials in many countries, and where AI helps in medical writing.
1:05:28 Medicine Forward Presentation - April 2026
A Wake Forest University School of Medicine panel with Ebony Boulware, Joseph Rigdon, Elizabeth Jensen and Kevin Ward Gibbs on research feasibility, study design and presenting data.
20:12 Operation Trailblazer: Rolling INDs, Outside Expert Submission Help, and One-Trial Requirement
The Cancer Letter looks at proposed changes to FDA, including an expedited Investigational New Drug program, which would use expertise outside FDA to help prepare INDs before submission.